Nurix (NRIX) grants CSO 93,750 options and 42,875 RSUs

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen received new equity awards on February 10, 2026. She was granted an option to buy 93,750 shares of common stock at $16.45 per share, vesting monthly over three years through February 9, 2029, subject to continued service.

Hansen was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in 12 equal quarterly installments over three years, beginning July 30, 2026, with shares delivered after each vesting date as long as she remains in service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hansen Gwenn

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	93,750	$0.00	--
Grant/Award	Restricted Stock Units	42,875	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 93,750 shares (Direct); Restricted Stock Units — 42,875 shares (Direct)

Footnotes (1)

1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$16.45	02/10/2026		A		93,750		(1)	02/09/2036	Common Stock	93,750	$0	93,750	D
Restricted Stock Units	$0(2)	02/10/2026		A		42,875		(3)	(4)	Common Stock	42,875	$0	42,875	D

Explanation of Responses:

1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

4. RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nurix Therapeutics (NRIX) report for Gwenn Hansen?

Nurix Therapeutics reported equity awards to Chief Scientific Officer Gwenn Hansen. She received 93,750 stock options at a $16.45 exercise price and 42,875 restricted stock units, both subject to multi‑year vesting tied to her continued service with the company.

How many stock options were granted to Nurix CSO Gwenn Hansen on February 10, 2026?

Gwenn Hansen received an option for 93,750 shares of Nurix common stock. The option has a $16.45 exercise price and vests in 36 equal monthly installments starting March 10, 2026, becoming fully vested on February 9, 2029, if she remains in service.

What are the vesting terms of Gwenn Hansen’s Nurix stock options?

The stock option vests as to 1/36 of the total shares each month. Vesting begins March 10, 2026 and continues until the option is fully vested on February 9, 2029, provided Hansen continues to provide services to Nurix on each vesting date.

How many restricted stock units did Nurix grant to CSO Gwenn Hansen?

Nurix granted 42,875 restricted stock units to Chief Scientific Officer Gwenn Hansen. Each RSU represents a contingent right to receive one share of common stock, subject to vesting conditions and potential cancellation if service requirements are not met before vest dates.

When do Gwenn Hansen’s Nurix restricted stock units start vesting?

The restricted stock units begin vesting on July 30, 2026. The award vests as to 1/12 of the total RSUs quarterly over three years, with Nurix common shares delivered to Hansen after each vesting date if she continues providing services.

Do the RSUs granted to Nurix CSO Gwenn Hansen have an expiration date?

The restricted stock units do not have a traditional expiration date. According to the disclosure, RSUs either vest on scheduled vesting dates or are canceled before vesting if the service conditions required for vesting are not satisfied by Hansen.